Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Real-world Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or B

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Have a diagnosis of haemophilia A or B and previously treated with factor Product~* Have started prophylactic Elocta/Alprolix treatment prior to enrollment visit, or at enrollment prescribed prophylactic treatment with Elocta or Alprolix regardless of participation in the study~* Signed and dated informed consent provided by the patient, or the patient's legally acceptable representative for patients under the legal age, Before any study-related activities are undertaken. Assent should be obtained from paediatric patients according to local regulations.~Exclusion Criteria:~* Participation in an investigational medicinal product trial, from four weeks prior to first injection with Elocta or Alprolix to enrollment visit.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Haemophilia A patients (Type: None): Elocta will be prescribed according to local practice and administered by patients with haemophilia A for prophylactic treatment
- Haemophilia B patients (Type: None): Alprolix will be prescribed according to local practice and administered by patients with haemophilia B for prophylactic treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).